Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose etoposide for refractory malignancies: a phase I study.

P E Postmus, N H Mulder, D T Sleijfer

    Cancer Treatment Reports
    |December 1, 1984
    PubMed
    Summary

    Etoposide shows effectiveness against solid tumors. High-dose etoposide therapy is feasible, with oropharyngeal mucositis as the dose-limiting toxicity, and is suitable for advanced cancer treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Early development of the metabolic syndrome after chemotherapy for testicular cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2012
    Same author

    Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors.

    Annals of oncology : official journal of the European Society for Medical Oncology·2009
    Same author

    Obstructive sleep apnea therapy.

    Journal of dental research·2008
    Same author

    [18 years experience with mechanical ventilation in patients with Duchenne muscular dystrophy].

    Nederlands tijdschrift voor geneeskunde·2007
    Same author

    111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

    European journal of cancer (Oxford, England : 1990)·2007
    Same author

    [From the poliomyelitis epidemic to the founding of artificial respiration centres, intensive care units and centres for home mechanical ventilation].

    Nederlands tijdschrift voor geneeskunde·2006

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Etoposide demonstrates activity against various solid tumors at standard doses.
    • Standard etoposide dosing is associated with mild myelosuppression and no extramedullary toxicity.
    • Dose-response relationships for etoposide have been supported by recent human studies.

    Purpose of the Study:

    • To escalate etoposide dosage in patients with advanced malignancies.
    • To identify the dose-limiting extramedullary toxicity of etoposide.
    • To evaluate the suitability of etoposide for high-dose chemotherapy regimens.

    Main Methods:

    • A dose-escalation study was conducted in 22 patients with progressive disseminated malignancies.
    • Etoposide was administered at escalating doses to determine toxicity thresholds.

    Related Experiment Videos

  • Patients were monitored for both bone marrow and extramedullary toxicities.

    • Main Results:

    • Oropharyngeal mucositis was identified as the dose-limiting extramedullary toxicity at 3.5 g/m2.
    • Bone marrow toxicity was reversible and not cumulative.
    • Partial responses were observed in 9 out of 22 patients.
    • Two of three patients with central nervous system metastases showed improvement.

    Conclusions:

    • Etoposide can be safely escalated to high doses.
    • High-dose etoposide therapy is a viable option for patients with advanced cancers.
    • The identified dose-limiting toxicity allows for safe dose optimization in clinical practice.